1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials
  4. >>Diversity & Inclusion

CRO Group Picks Seven US Sites To Reap Big Gains In Trial Diversity

 
• By Vibha Sharma

The Association of Clinical Research Organizations has awarded “seed funding” to seven US-based community clinical trial sites to demonstrate proof-of-concept projects aimed at increasing diversity in clinical trials.

Closeup of a support hands. Closeup shot of a young woman holding a senior man's hands in comfort. Female carer holding hands of senior man
Leveraging Community Knowledge And Relationships Can Enhance Clinical Trial Diversity (Shutterstock)
Key Takeaways
  • The global clinical research organization, ACRO, has awarded grants to seven US-based clinical trial sites to support innovative projects aimed at improving diversity and inclusion.
  • The grants, ranging from $25,000 to $50,000, are intended to demonstrate that even small investments can significantly improve representation in clinical trials, serving as proof-of-concept initiatives.
  • The funded projects include a range of initiatives such as training workshops on cultural competency, community engagement projects, technology updates, and targeted marketing campaigns to enhance participant diversity.
  • The future of diversity, equity and inclusion projects is uncertain under President Donald Trump’s second term and ACRO says it is waiting to see the full impact and scope of the new administration’s priorities.

Seven US-based clinical trial sites with innovative ideas to improve diversity and inclusion in their studies, through measures such as better outreach and training, have received grants from the Association...

The grants will support seven projects proposed by the shortlisted sites “as proof-of-concept initiatives to show the broader industry that a small investment can go a long way toward improving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Makary Signals Some Interest In US FDA Staff Cuts, Fighting Patent Thickets

 
• By Sarah Karlin-Smith

The FDA Commissioner nominee also commented on trial diversity, the role of public comment and expedited biosimilar reviews during his Senate confirmation hearing.

US FDA Says Restored Webpages Do Not Reflect ‘Biological Reality’

 
• By Sue Sutter

Clinical trial draft guidance webpages are back online following a court order, but with new language disclaiming any information promoting gender ideology as "extremely inaccurate."

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.